# A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

> **NCT01083615** · PHASE3 · TERMINATED · sponsor: **Achieve Life Sciences** · enrollment: 14 (actual)

## Conditions studied

- Castrate-Resistant Prostate Cancer
- Hormone Refractory Prostate Cancer

## Interventions

- **DRUG:** custirsen sodium
- **DRUG:** isotonic, 0.9% sodium chloride
- **DRUG:** docetaxel
- **DRUG:** cabazitaxel
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT01083615
- **Lead sponsor:** Achieve Life Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-03
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Unable to enroll due to criteria for stable baseline pain
- **Last updated:** 2016-10-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01083615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01083615, "A Study Evaluating the Pain Palliation Benefit of Adding Custirsen to Docetaxel Retreatment or Cabazitaxel as Second Line Therapy in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01083615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*